Different pharmacokinetic and pharmacological effects following acute and chronic treatment with imipramine.
Two schedules of imipramine (IM) administration were compared, a single intraperitoneal dose (10 mg/kg) (I) and chronic oral dosage (10 mg/kg twice a day for 14 days) (II). During schedule I, IMI reached maximal concentration in brain twice as high as that of its metabolite, desipramine (DMI), but disappeared more rapidly. During schedule II, DMI achieved concentrations twice as high as those of IMI which were maintained in a long-lasting plateau and there were considerable differences in areas of brain concentration curves. During schedule I, depletion of brain noradrenaline (NA) induced by H77/77 and of 5-hydroxytryptamine (5-HT) by p-chloro-amphetamine, were inhibited. During schedule II, after DMI concentration had become high and that of IMI low, only NA depletion but not that of 5-HT, was inhibited. At the same time, fenfluramine-induced hyperthermia was not antagonized although it was inhibited in schedule I. These findings may be relevant to those obtained clinically and may help to shed light on mechanisms of antidepressant action.
D000818:Animals; D001923:Brain Chemistry; D003891:Desipramine / Q000032:analysis; D005277:Fenfluramine / Q000494:pharmacology; D005334:Fever / Q000139:chemically induced; D007099:Imipramine / Q000008:administration & dosage / Q000032:analysis / Q000494:pharmacology*; D008297:Male; D009638:Norepinephrine / Q000032:analysis; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000032:analysis; D013997:Time Factors
D005277:Fenfluramine; D012701:Serotonin; D007099:Imipramine; D003891:Desipramine; D009638:Norepinephrine